CO6561789A2 - Método de tratamiento - Google Patents

Método de tratamiento

Info

Publication number
CO6561789A2
CO6561789A2 CO12113697A CO12113697A CO6561789A2 CO 6561789 A2 CO6561789 A2 CO 6561789A2 CO 12113697 A CO12113697 A CO 12113697A CO 12113697 A CO12113697 A CO 12113697A CO 6561789 A2 CO6561789 A2 CO 6561789A2
Authority
CO
Colombia
Prior art keywords
treatment method
treatment
hydrates
administration
patient
Prior art date
Application number
CO12113697A
Other languages
English (en)
Inventor
Iordache Valeriu Damian
Acosta Andrew King
Megan M Mclaughlin
Albert B Suttle
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Publication of CO6561789A2 publication Critical patent/CO6561789A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento de trastornos de angiogénesis ocular o filtración vascular en un paciente, mediante la administración de inhibidores adecuados, incluyendo pazopanib o sales farmacéuticamente aceptables o hidratos del mismo.
CO12113697A 2010-01-06 2012-07-06 Método de tratamiento CO6561789A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29274710P 2010-01-06 2010-01-06

Publications (1)

Publication Number Publication Date
CO6561789A2 true CO6561789A2 (es) 2012-11-15

Family

ID=44305773

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12113697A CO6561789A2 (es) 2010-01-06 2012-07-06 Método de tratamiento

Country Status (20)

Country Link
US (1) US20130012531A1 (es)
EP (1) EP2521550A4 (es)
JP (1) JP2013516472A (es)
KR (1) KR20120125244A (es)
CN (1) CN102781450A (es)
AU (1) AU2011203706A1 (es)
BR (1) BR112012016673A2 (es)
CA (1) CA2786328A1 (es)
CL (1) CL2012001852A1 (es)
CO (1) CO6561789A2 (es)
DO (1) DOP2012000174A (es)
EA (1) EA201290603A1 (es)
IL (1) IL220594A0 (es)
MA (1) MA33991B1 (es)
MX (1) MX2012007875A (es)
PE (1) PE20121523A1 (es)
SG (1) SG181826A1 (es)
TW (1) TW201201808A (es)
UY (1) UY33164A (es)
WO (1) WO2011085007A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
ES2656292T3 (es) * 2012-05-01 2018-02-26 Translatum Medicus Inc. Métodos de tratamiento y diagnóstico de enfermedades oculares que causan ceguera
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
AU2015301054B2 (en) 2014-08-08 2020-05-14 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
MX2017015838A (es) * 2015-06-06 2018-08-15 Cloudbreak Therapeutics Llc Composiciones y metodos para tratar pterigion.
US10323349B2 (en) * 2015-09-25 2019-06-18 Kyoudojyutaku Co., Ltd. Washing system
MX2018014868A (es) 2016-06-02 2019-09-13 Cloudbreak Therapeutics Llc Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1343782T1 (sl) * 2000-12-21 2009-10-31 Smithkline Beecham Corp Pirimidinamini kot modulatorji angiogeneze
DK1968594T3 (da) * 2005-11-29 2010-12-13 Glaxosmithkline Llc Behandling af okulære neovaskulære lidelser, såsom makulær degeneration, striae angioides og makulært ødem
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
US20090325959A1 (en) * 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
KR20120049267A (ko) * 2009-07-16 2012-05-16 글락소 웰컴 매뉴팩쳐링 피티이 엘티디 치료 방법

Also Published As

Publication number Publication date
MX2012007875A (es) 2012-08-03
CN102781450A (zh) 2012-11-14
EA201290603A1 (ru) 2013-03-29
EP2521550A1 (en) 2012-11-14
MA33991B1 (fr) 2013-02-01
WO2011085007A1 (en) 2011-07-14
EP2521550A4 (en) 2013-07-03
KR20120125244A (ko) 2012-11-14
JP2013516472A (ja) 2013-05-13
PE20121523A1 (es) 2012-12-12
UY33164A (es) 2011-08-31
SG181826A1 (en) 2012-07-30
TW201201808A (en) 2012-01-16
BR112012016673A2 (pt) 2018-06-05
CA2786328A1 (en) 2011-07-14
CL2012001852A1 (es) 2012-11-30
DOP2012000174A (es) 2012-12-15
IL220594A0 (en) 2012-08-30
US20130012531A1 (en) 2013-01-10
AU2011203706A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
CO6561789A2 (es) Método de tratamiento
CY1120334T1 (el) Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
IN2014DN09434A (es)
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
WO2013052699A3 (en) Novel quinoxaline inhibitors of pi3k
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
MX2014000746A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il benzamidas como inhibidores de tirosina cinasa de bruton.
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
UA113750C2 (xx) Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
CR20140052A (es) Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201190337A1 (ru) Способ лечения
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
WO2013166037A9 (en) Non-retinoid antagonists for treatment of eye disorders

Legal Events

Date Code Title Description
FC Application refused